Bristol-Myers Squibb entered a worldwide collaboration with Janssen to develop and commercialize Bristol Myers Squibb’s Factor XIa inhibitor program, including BMS-986177, an investigational anticoagulant compound being studied for prevention and treatment of major thrombotic conditions.
Janssen will pay Bristol Myers Squibb an upfront sum along with potential development and regulatory milestone payments. The companies will share development costs and commercial profits and losses. Additional terms of the agreement were not disclosed.
Bristol Myers Squibb has a strong heritage of pioneering research and development of novel assets to address areas of high unmet need for patients with serious cardiovascular conditions. The collaboration will leverage both companies’ resources and expertise to establish a broad development program across multiple indications.